Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -136.91% is 36% above its 5-year average of -214.88%, near the high end of its 5-year range (-946.29%–-23.80%).
50.95% below its 12-month average of -90.70%.
Reported quarterly return on assets; no daily interpolation. Q3 FY2026 (2026-04-30): -26.47%.
RETURN ON ASSETS (ROA)
-136.91%
RETURN ON ASSETS (ROA) AVG TTM
-90.70%
RETURN ON ASSETS (ROA) AVG 3Y
-79.79%
RETURN ON ASSETS (ROA) AVG 5Y
-214.88%
RETURN ON ASSETS (ROA) AVG 10Y
-324.68%
RETURN ON ASSETS (ROA) AVG 15Y
-107.84%
RETURN ON ASSETS (ROA) AVG 20Y
-87.45%
CURRENT VS TTM AVG
-50.95%
CURRENT VS 3Y AVG
-71.58%
CURRENT VS 5Y AVG
+36.28%
CURRENT VS 10Y AVG
+57.83%
CURRENT VS 15Y AVG
-26.95%
CURRENT VS 20Y AVG
-56.57%
SECTOR MEDIAN · HEALTHCARE
-29.15%
median of 609 covered companies
CURRENT VS SECTOR MEDIAN
-369.67%
vs the sector median at left
BriaCell Therapeutics Corp.
Market Cap
$34.89M
Return on Assets (ROA)
-136.91%
TTM Avg
-90.70%
3Y Avg
-79.79%
5Y Avg
-214.88%
Market Cap
$35.42M
Return on Assets (ROA)
118.69%
TTM Avg
-31.86%
3Y Avg
-49.56%
5Y Avg
-43.59%
Market Cap
$36.00M
Return on Assets (ROA)
-11.09%
TTM Avg
-5.71%
3Y Avg
-4.17%
5Y Avg
-3.19%
Market Cap
$33.69M
Return on Assets (ROA)
-42.84%
TTM Avg
-15.31%
3Y Avg
-31.73%
5Y Avg
-29.34%
Market Cap
$36.13M
Return on Assets (ROA)
-120.78%
TTM Avg
-168.59%
3Y Avg
-147.82%
5Y Avg
-131.31%
Market Cap
$36.48M
Return on Assets (ROA)
-103.00%
TTM Avg
-39.81%
3Y Avg
-17.36%
5Y Avg
-12.69%
Market Cap
$33.22M
Return on Assets (ROA)
-190.81%
TTM Avg
-476.65%
3Y Avg
-339.92%
5Y Avg
-580.90%
Market Cap
$36.59M
Return on Assets (ROA)
-56.04%
TTM Avg
-32.94%
3Y Avg
-18.68%
5Y Avg
-12.05%
Market Cap
$33.15M
Return on Assets (ROA)
-114.53%
TTM Avg
-107.26%
3Y Avg
-84.46%
5Y Avg
-72.21%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BriaCell Therapeutics Corp. (BCTX) | $34.89M | -136.91% | -90.70% | -79.79% | -214.88% |
| Elutia Inc (ELUT)vs › | $35.42M | 118.69% | -31.86% | -49.56% | -43.59% |
| Accuray Incorporated (ARAY)vs › | $36.00M | -11.09% | -5.71% | -4.17% | -3.19% |
| Grace Therapeutics, Inc. (GRCE)vs › | $33.69M | -42.84% | -15.31% | -31.73% | -29.34% |
| Elicio Therapeutics, Inc. (ELTX)vs › | $36.13M | -120.78% | -168.59% | -147.82% | -131.31% |
| DocGo Inc. (DCGO)vs › | $36.48M | -103.00% | -39.81% | -17.36% | -12.69% |
| HeartBeam, Inc. (BEAT)vs › | $33.22M | -190.81% | -476.65% | -339.92% | -580.90% |
| iTonic Holdings Ltd. (ITOC)vs › | $36.59M | -56.04% | -32.94% | -18.68% | -12.05% |
| Aligos Therapeutics, Inc. (ALGS)vs › | $33.15M | -114.53% | -107.26% | -84.46% | -72.21% |
| EUDA Health Holdings Limited (EUDA)vs › | $32.78M | -277.36% | -524.61% | -478.10% | -316.43% |
ROA
-136.9%
ROE
-154.1%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-07-31 | -122.60% |
| 2024-07-31 | -58.80% |
| 2023-07-31 | -74.74% |
| 2022-07-31 | -63.04% |
| 2021-07-31 | -23.80% |
| 2020-07-31 | -946.29% |
| 2019-07-31 | -1308.35% |
| 2018-07-31 | -236.66% |
| 2017-07-31 | -196.65% |
| 2016-07-31 | -267.04% |
| 2015-07-31 | -273.54% |
| 2014-07-31 | -37205.59% |
| 2013-07-31 | -4.06% |
| 2012-07-31 | -9.68% |
| 2011-07-31 | -8.31% |
| 2010-07-31 | -63.02% |
| 2009-07-31 | -23.67% |
| 2008-07-31 | -26.65% |
| 2007-07-31 | -25.42% |
| 2006-07-31 | -8.90% |
